TAMPERE, Finland, May 15, 2026 /PRNewswire/ — Bioretec Ltd. | Company announcement | 15 May 2026 at 9:00 a.m.
This announcement summarizes Bioretec Ltd’s business review for January-March 2026. The complete business review is attached to this release as a PDF file and available on the company’s website at https://investors.bioretec.com/en/reports_and_presentations.
January–March 2026 in brief
- Net sales amounted to EUR 1,220 thousand (1–3/2025: EUR 1,396 thousand)
- Adjusted sales margin was 70.1% (56.7%) of net sales. From Q1/2026, the company will transition to reporting adjusted sales margin to be aligned with industry reporting standards. Adjusted sales margin comprises the net sales of implants deducted by related cost of sales and extraordinary expenses.
- EBITDA was EUR -1,375 (-1,236) thousand
- The result for the reporting period amounted to EUR -1,371 (-1,298) thousand
- On March 27, Bioretec announced that the Board of Directors has resolved on a rights issue
- The rights issue was completed after the end of the reporting period. The final results of the rights issue show that a total of 1,286,801,534 new shares were subscribed for in the offering, corresponding to approximately 87.1 per cent of the 1,477,828,416 new shares offered in the offering. The subscription price in the offering was EUR 0.01 per new share. Bioretec receives gross proceeds of approximately EUR 12.9 million from the offering.
Key figures
|
EUR 1,000 unless otherwise indicated |
1–3/2026 |
1–3/2025 |
Change, % |
1–12/2025 |
|
Net sales |
1,220 |
1,396 |
-12.6 % |
3,522 |
|
Adjusted sales margin, % of net sales 1 |
70.1 % |
56.7 % |
59.3 % |
|
|
EBITDA |
-1,375 |
-1,236 |
-8,476 |
|
|
EBIT |
-1,435 |
-1,287 |
-8,686 |
|
|
Profit / loss for the period |
-1,371 |
-1,298 |
-9,483 |
|
|
R&D expenditure, % of net sales |
47.3 % |
45.7 % |
85.8 % |
|
|
Equity ratio, % |
82.2 % |
82.2 % |
84.3 % |
|
|
Cash and cash equivalents |
1,880 |
4,424 |
-57.5 % |
4,126 |
|
Earnings per share (undiluted) |
-0.04 |
-0.06 |
-0.34 |
|
|
Earnings per share (diluted) |
-0.04 |
-0.05 |
-0.28 |
|
|
Number of shares |
30,788,092 |
23,336,858 |
30,788,092 |
|
|
Number of shares (diluted) |
33,821,751 |
27,515,133 |
33,821,751 |
|
|
Number of personnel at the end of the period |
60 |
48 |
25.0 % |
60 |
|
1 From Q1/2026, the company will transition to reporting adjusted sales margin to be aligned with industry reporting |
||||
Net sales by geographical area
|
EUR 1,000 |
1–3/2026 |
1–3/2025 |
Change, % |
1–12/2025 |
|
Europe |
434 |
143 |
203.3 % |
887 |
|
The U.S. |
292 |
53 |
449.0 % |
488 |
|
Rest of the World |
494 |
1,200 |
-58.8 % |
2,146 |
|
Total |
1,220 |
1,396 |
-12.6 % |
3,522 |
CEO Sarah van Hellenberg Hubar-Fisher’s comments
Early traction from renewed strategy
The first quarter of 2026 reflects intentional direction and early traction from the operational and commercial reset initiated in the second half of 2025. Net sales reached EUR 1.2 million, with growth in both the U.S. and Europe reaching 449% and 203.3% respectively for the year-over-year comparison period. This growth is not only volume-driven but structurally healthier: revenue is now supported by a broader mix of customers and distribution partners across key markets. Adjustments to gross margins were made in an effort to align our financial reporting more closely with that of our industry peers, an initiative we identified in 2025 and implemented at the start of this financial year.
During the quarter, we activated new distribution channels in the U.S. and internationally while expanding our direct customer base. This reduces concentration risk and improves the quality and resilience of our revenue as we scale. The focus is clear – build a commercially robust business in high-value markets with repeatable demand drivers.
Our strategy for 2026–2028 prioritizes disciplined execution, capital efficiency, and continued innovation through the expansion of the RemeOs™ platform. The first quarter of 2026 already provided clear signals that the updated strategy is translating into measurable results. The commercial investments made in late 2025, particularly in leadership and capability building, are accelerating our momentum both in the U.S. and Europe.
We have continued to strengthen our market presence and visibility, particularly in the United States. During the quarter, we further established our Key Opinion Leader (KOL) program, including hosting our first KOL roundtable in January and launching a series of monthly surgeon-led webinars. In addition, we presented at several important industry events, including the AOFAS winter meeting, the ACFAS annual scientific conference, the Canaccord Genuity Musculoskeletal Conference and the AAOS Annual Meeting in New Orleans in March. These activities enhance our engagement with clinical and economic stakeholders and support broader awareness of our technology in the world’s largest medtech market.
Looking ahead, we remain focused on driving commercial growth, advancing launch readiness for our near-term pipeline, and driving operational excellence. Advancing production capabilities and process discipline is a priority to ensure that growth is supported by reliable and efficient delivery.
Successful rights issue supports the next phase of targeted growth
After the reporting period, we successfully completed a rights issue. This strengthens our financial position and provides additional resourcing required to execute the next phase of our targeted growth. Specifically, it allows us to progress the execution of our strategy with a focus on the near-term pipeline, U.S. commercial organization and operational scale. We are greatly encouraged by the outcome of the rights issue and grateful for the continued commitment from our shareholders.
We carry this momentum into 2026 with a strengthened financial base, clear operational priorities, and an organizational focus with an emphasis on execution.
Significant events in January–March 2026
- On January 15, Bioretec announced the appointment of Tuukka Paavola as Chief Financial Officer and part of the management team.
- On February 13, Bioretec announced that its Board of Directors is assessing a potential rights issue in the near future.
- On March 10, Bioretec announced that it is planning a rights issue of at least EUR 5 million and up to EUR 15 million with a maximum of 1,500,000,000 new shares.
- On March 10, Bioretec issued a notice of an Extraordinary General Meeting to be held on March 27, 2026.
- On March 12, Bioretec announced that Chief Technology Officer Timo Lehtonen will transition to the role of External Executive Advisor (Technology & Strategy) and step down from the management team and CTO role as of July 6, 2026. Bioretec is establishing two new dedicated roles to cover the day-to-day operational needs in both product development and clinical affairs, and recruitment efforts are already underway.
- On March 26, Bioretec announced that The Finnish Financial Supervisory Authority has granted Stephen Industries Inc Oy and Kustaa Poutiainen a permanent exemption from the obligation to launch a mandatory public takeover bid relating to the upcoming rights issue.
- On March 27, Bioretec announced the resolutions of the Extraordinary General Meeting and that the Board of Directors has resolved on a rights issue of up to approximately EUR 14.8 million.
Significant events after the reporting period
- On April 2, Bioretec published an exemption document relating to its rights issue.
- On April 20, Bioretec published the notice to the Annual General Meeting to be held on May 8, 2026.
- On April 23 and April 24, Bioretec published the preliminary and final results of the rights issue, respectively. The final results of the rights issue show that a total of 1,286,801,534 new shares were subscribed for in the offering, corresponding to approximately 87.1 per cent of the 1,477,828,416 new shares offered in the offering. The subscription price in the offering was EUR 0.01 per new share. Bioretec receives gross proceeds of approximately EUR 12.9 million from the offering.
- On April 28, Bioretec announced that 1,286,801,534 new shares subscribed for in the rights issue and 24,196,337 new shares issued to Stephen Industries Inc Oy as underwriting fee pursuant to the underwriting commitment have been registered with the trade register maintained by the Finnish Patent and Registration Office. In addition, Bioretec announced that it adjusts the terms and conditions of its stock option programs due to the completed rights issue.
- On May 8, Bioretec announced the resolutions of the Annual General Meeting and the constitutive meeting of the Board of Directors held on the same date.
- On May 13, Bioretec announced that it clarifies its 2026–2028 financial target regarding the sales margin to concern the adjusted sales margin.
Financial reporting in 2026
In 2026, Bioretec will publish the following financial reports:
- Half-year report for January–June 2026 on Thursday, August 13, 2026
- Business review for January–September 2026 on Thursday, November 12, 2026
The releases will be published as company releases and will be available online on Bioretec’s website at https://investors.bioretec.com/en/reports_and_presentations.
Tampere, May 15, 2026
Board of Directors
Bioretec Ltd.
For additional information:
Sarah van Hellenberg Hubar-Fisher
CEO
+31 6 1544 8736
sarah.hubar-fisher@bioretec.com
Tuukka Paavola
CFO
+358 50 386 0013
tuukka.paavola@bioretec.com
Certified Adviser
Nordic Certified Adviser AB, +46 70 551 67 29
Information about Bioretec
Bioretec is a globally operating Finnish medical device pioneer at the forefront of transforming orthopedic care with fully biodegradable implant technologies. The company has built unique competencies in the biological interface of active implants to enhance bone growth and accelerate fracture healing after orthopedic surgery. The products developed and manufactured by Bioretec are used worldwide in approximately 40 countries.
The company’s latest innovation, the RemeOs™ product line, is based on a high-performance magnesium alloy and hybrid composite, introducing a new generation of strong absorbable materials for enhanced surgical outcomes. The RemeOs implants are absorbed and replaced by bone, which eliminates the need for removal surgery while facilitating fracture healing. The first RemeOs product market authorization was received in the U.S. in March 2023, and in Europe, the CE mark approval was received in January 2025.
Bioretec’s Activa product line features fully bioabsorbable orthopedic implants made from a proprietary, self-reinforced PLGA both CE marked and FDA cleared for a wide range of indications in adult and pediatric patients.
Bioretec is shaping the future of orthopedic treatment with a focus on healing through absorption, paving the way for more effective and patient-friendly solutions.
To learn more about Bioretec, visit www.bioretec.com
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
|
Bioretec ENG Q1 2026 |
View original content:https://www.prnewswire.co.uk/news-releases/bioretec-ltds-business-review-q1-2026-early-traction-from-renewed-strategy-302773366.html
Disclaimer: The above press release comes to you under an arrangement with PR Newswire. TheNewsThisWeek.co.uk takes no editorial responsibility for the same.